Amplia

Be first to know our latest company updates

Watch exclusive videos accompanying major news

Home

Science

Clinical Trial

Shareholder Services

US Shareholders

Investor Fact Sheet

Share Price

Announcements

Reports

Research Reports

Investor FAQs

Updates

Top 20 Shareholders

Investor Centre

Presentations

In the News

Video Updates

Communication

Company Overview

Corporate Directory

Corporate Governance

Board

Team

Clinical Advisers

Values

About Us

Webinars

Contact

Montserrat

Amplia Therapeutics Limited

Amplia (ASX:ATX) has today announced it is undertaking a fully underwritten Entitlement Offer to raise $4.27m. Under the Entitlement Offer, eligible shareholders will be able to subscribe for two (2) New Shares for every five (5) shares held.

Funds from this capital raise will be used to support Amplia’s ongoing Phase 2a ACCENT trial and undertake the Interim Analysis, produce additional narmafotinib and manufacture a further batch of 25,000 capsules, and support a pilot Investigator Initiated Trial in ovarian cancer.

Click link below to read the full ASX Release.

Entitlement Offer to raise $4.27m